Pharmacologic epichaperome inhibition by PU-AD rebalanced activity of networks to pre-tau overexpression states (Fig. 6a, b), and confirmed epichaperomes as mediators of tau-induced functional imbalances in synaptic pathways. This evidence concerns the gene MAPT and Alzheimer disease.